Healthcare Companies in the News for July 10 - Pharmacyclics, Celldex Therapeutics, Pfizer, Nu Skin

    Healthcare Companies in the News for July 10 - Pharmacyclics, Celldex
                        Therapeutics, Pfizer, Nu Skin

PR Newswire

CORAL SPRINGS, Florida, July 10, 2013

CORAL SPRINGS, Florida, July 10, 2013 /PRNewswire/ -- issues market news updates for today's active
healthcare companies Pharmacyclics, Inc. (Nasdaq: PCYC), Celldex Therapeutics,
Inc. (Nasdaq:CLDX), Pfizer Inc. (NYSE: PFE) and Nu Skin Enterprises, Inc.

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has submitted a New
Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the
investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for
two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma
(MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
The submission was based on data from Phase II studies in patients with
relapsed/refractory MCL and in patients with relapsed/refractory CLL/SLL. With
this submission, Pharmacyclics is also requesting Priority Review.
Pharmacyclics is jointly developing ibrutinib with Janssen.
Read the entire press release at

Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today that the United
States Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029
entitled "Human immune therapies using a CD27 agonist alone or in combination
with other immune modulators" which broadly supports the Company's product
candidate CDX-1127. CD27, a signaling molecule expressed on T lymphocytes, can
be effectively manipulated with activating antibodies to induce potent
anti-tumor responses and, due to the restricted expression and regulation of
CD27, may result in less toxicity--overcoming a key barrier that other targets
in this class have faced. CDX-1127 is a fully human monoclonal antibody (mAb)
that targets CD27 and is currently in Phase 1 clinical development for the
treatment of solid tumors and hematologic malignancies.
Read the entire press release at

Pfizer Inc. (NYSE: PFE) announced today the company's pneumococcal conjugate
vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine
[13-valent, adsorbed]), received European approval for an expanded indication
to include adults aged 18 to 49 years for active immunization for the
prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae
(S. pneumoniae).(1) Previously approved in the European Union (EU) for use in
infants, young children and adolescents aged 6 weeks to 17 years, as well as
adults 50 years of age and older, Prevenar 13 is now the only pneumococcal
vaccine in the EU that offers protection against invasive disease from infancy
through adulthood.(1) The European Commission is the first to approve Prevenar
13 to offer protection against invasive disease at all stages of life.
Read the entire press release at

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced a significant increase
to estimated revenue and earnings per share for the second quarter of 2013.
Revenue is now estimated to be about $680 million, with estimated earnings per
share of approximately $1.20. Foreign currency fluctuations negatively
impacted second-quarter revenue by approximately 3 percent. Prior revenue
guidance was $570 to $580 million, with earnings per share guidance of $0.91
to $0.95. Additionally, the company announced that it is increasing its
full-year 2013 revenue guidance by $320 million to $2.83 to $2.86 billion,
including a negative 5 percent impact from foreign currency fluctuations. The
company now expects 2013 earnings to be $4.85 to $5.00 per share.
Read the entire press release at is leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visit for more
details. Get an edge on the market with ourPremium News Alerts that are
FREE for a limited time at Follow us on
Facebook: and

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1-(954)345-0611

Press spacebar to pause and continue. Press esc to stop.